Cardiovascular outcomes of liraglutide in patients with type 2 diabetes: A systematic review and meta-analysis
Conclusions:
In conclusion, our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and cardiovascular death among patients with type 2 diabetes.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research
More News: Cardiology | Cardiovascular | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Heart Attack | Internal Medicine | Stroke | Study | Victoza